⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 23, 2024

[The efficacy and safety of anlotinib combined with niraparib in treating patients with platinum-resistant recurrent ovarian cancer].

Mingjin Yang Jinxi Wang Shan Deng Shujia Liang Lei Sun

View at Publisher

Ask AI

Bookmark

Share

Abstract

To investigate the efficacy and safety of anlotinib combined with niraparib in treating patients with platinum-resistant ovarian cancer.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yang et al. (2024) studied this question.

synapsesocial.com/papers/68e5f62bb6db64358758a9c8 https://doi.org/10.3760/cma.j.cn112152-20231024-00224

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Synergistic Effects of Niraparib and Anlotinib on Suppressing the Growth of Ovarian Cancer and Stem-Like Cells by Inhibiting PI3K/Akt Signalling2024 · 2 citations
2Anlotinib plus hormone therapy in patients with platinum-resistant recurrent ovarian cancer: A prospective, single-arm, open-label, phase II study.2024
3Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination–deficient stage III/IV ovarian cancer: Findings from cohort C of the OPAL phase 2 trialEarly-Phase Clinical Trial · 2026
4Efficacy of niraparib in patients with advanced ovarian cancer: A meta-analysis of randomized controlled trials.2024
5A phase II study of anlotinib plus albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or peritoneal carcinomar (A-Plus trial): Updated efficacy and safety.2024

More related papers

155P Safety and efficacy of niraparib in Japanese recurrent ovarian cancer patients: Maintenance therapy for platinum-sensitive recurrence and late-line monotherapy2026
Olaparib and niraparib as maintenance therapy in patients with newly diagnosed and platinum-sensitive recurrent ovarian cancer: A single-center study in China2024
Preliminary efficacy and safety of first-line anlotinib plus carboplatin/paclitaxel induction therapy followed by anlotinib maintenance in advanced ovarian cancer: Results from the ALTER-GO-010 phase II multicenter trial.2026